Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: A systematic review and metaanalysis of observational studies

American Journal of Gastroenterology

Volumn 100, Issue 6, 2005, Pages 1345-1353

  Velayos, Fernando S ^b   Terdiman, Jonathan P ^a   Walsh, Judith M ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BALSALAZIDE; MESALAZINE; OLSALAZINE; SALAZOSULFAPYRIDINE;

CALCULATION; CANCER RISK; CASE CONTROL STUDY; CHEMOPROPHYLAXIS; CLINICAL TRIAL; COHORT ANALYSIS; COLORECTAL CANCER; COLORECTAL DYSPLASIA; DYSPLASIA; FOLLOW UP; HUMAN; LONG TERM CARE; MEDICAL LITERATURE; META ANALYSIS; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVIEW; STATISTICAL MODEL; SYSTEMATIC REVIEW; TREATMENT OUTCOME; ULCERATIVE COLITIS;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CLINICAL TRIALS; COLITIS, ULCERATIVE; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MESALAMINE; MIDDLE AGED; MODELS, STATISTICAL; OBSERVATION; PUBLICATION BIAS; RETROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME;

EID: 21344446543     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2005.41442.x     Document Type: Review

References (26)

1. Choi PM, Zelig MP. Similarity of colorectal cancer in Crohn's disease and ulcerative colitis: Implications for carcinogenesis and prevention. Gut 1994;35:950-54.
2. Lennard-Jones JE. Cancer risk in ulcerative colitis: Surveillance or surgery. Br J Surg 1985;72(Suppl):S84-6.
3. Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: A meta-analysis. Gut 2001;48:526-35.
4. Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: A proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. Jama 2000;283:2008-12.
5. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-88.
6. West S, King V, Carey TS, et al. Systems to rate the strength of scientific evidence. Evidence Report/Technology Assessment No. 47 (Prepared by the Research Triangle Institute-University of North Carolina Evidence-Based Practice Center under Contract No. 290-97-0011), AHRQ Publication No. 02-E016. Agency for Healthcare Research and Quality, Rockville, MD, April 2002.
7. Juni P, Witschi A, Bloch R, et al. The hazards of scoring the quality of clinical trials for meta-analysis. JAMA 1999;282:1054-60.
8. Corley DA, Kerlikowske K, Verma R, et al. Protective association of aspirin/NSAIDs and esophageal cancer: A systematic review and meta-analysis. Gastroenterology 2003;124:47-56.
9. Lashner BA, Heidenreich PA, Su GL, et al. Effect of folate supplementation on the incidence of dysplasia and cancer in chronic ulcerative colitis. A case-control study. Gastroenterology 1989;97:255-9.
10. Pardi DS, Loftus EV, Jr, Kremers WK, et al. Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. Gastroenterology 2003;124:889-93.
11. Moody GA, Jayanthi V, Probert CS, et al. Long-term therapy with sulphasalazine protects against colorectal cancer in ulcerative colitis: A retrospective study of colorectal cancer risk and compliance with treatment in Leicestershire. Eur J Gastroenterol Hepatol 1996;8:1179-83.
12. Lashner BA, Provencher KS, Seidner DL, et al. The effect of folic acid supplementation on the risk for cancer or dysplasia in ulcerative colitis. Gastroenterology 1997;112:29-32.
13. Lindberg BU, Broome U, Persson B. Proximal colorectal dysplasia or cancer in ulcerative colitis. The impact of primary sclerosing cholangitis and sulfasalazine: Results from a 20-year surveillance study. Dis Colon Rectum 2001;44:77-85.
14. Pinczowski D, Ekbom A, Baron J, et al. Risk factors for colorectal cancer in patients with ulcerative colitis: A case-control study. Gastroenterology 1994;107:117-20.
15. Eaden J, Abrams K, Ekbom A, et al. Colorectal cancer prevention in ulcerative colitis: A case-control study. Aliment Pharmacol Ther 2000;14:145-53.
16. Bernstein CN, Blanchard JF, Metge C, et al. Does the use of 5-aminosalicylates in inflammatory bowel disease prevent the development of colorectal cancer? Am J Gastroenterol 2003;98:2784-8.
17. Rutter M, Saunders B, Wilkinson K, et al. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology 2004;126:451-9.
18. Tung BY, Emond MJ, Haggitt RC, et al. Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Ann Intern Med 2001;134:89-95.
19. Rubin DT, Djordjevic A, Huo D, et al. Use of 5-ASA is associated with decreased risk of dysplasia and colon cancer (CRC) in ulcerative colitis [abs]. Gastroenterology 2003;124:A: 279.
20. Van Staa TP, Card T, Leufkens HG, et al. Prior aminosalicylate use and the development of colorectal cancer in inflammatory bowel disease (IBD): A large British epidemiological study [abs]. Am J Gastroenterol 2003:A: 55.
21. Thun MJ, Namboodiri MM, Heath CW, Jr. Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 1991;325:1593-6.
22. Smalley W, Ray WA, Daugherty J, et al. Use of nonsteroidal anti-inflammatory drugs and incidence of colorectal cancer: A population-based study. Arch Intern Med 1999;159:161-6.
23. Muscat JE, Stellman SD, Wynder EL. Nonsteroidal antiinflammatory drugs and colorectal cancer. Cancer 1994;74:1847-54.
24. Ahnfelt-Ronne I, Nielsen OH, Christensen A, et al. Clinical evidence supporting the radical scavenger mechanism of 5-aminosalicylic acid. Gastroenterology 1990;98:1162-9.
25. Allgayer H. Review article: Mechanisms of action of mesalazine in preventing colorectal carcinoma in inflammatory bowel disease. Aliment Pharmacol Ther 2003;18(Suppl 2):10-4.
26. D'Inca R, Cardin R, Benazzato L, et al. Oxidative DNA damage in the mucosa of ulcerative colitis increases with disease duration and dysplasia. Inflamm Bowel Dis 2004;10:23-7.